4. Corcept Therapeutics (NASDAQ:CORT)
Upside Potential: 174.5%
Corcept Therapeutics (NASDAQ: CORT) ranks fourth in our list of biotechnology stocks with more than 50% upside, and the company stands out as one of the few biotechnology firms operating with a combination of commercialized therapies and an expanding clinical pipeline. Unlike many early-stage biotech companies, Corcept already generates revenue from approved treatments while continuing to develop new drugs targeting endocrine and oncology disorders.
The company’s research focuses on therapies designed to regulate cortisol activity, a hormone that plays a significant role in metabolic disorders, certain cancers, and neurological conditions. Its experimental drug relacorilant has emerged as a major focus of investor attention due to its potential applications in multiple therapeutic areas, including ovarian cancer and Cushing’s syndrome.
Analysts remain optimistic despite recent regulatory challenges. Canaccord Genuity analyst Edward Nash reiterated his Buy rating on the stock while forecasting a price target of $100 per share. Meanwhile, H.C. Wainwright analyst Swayampakula Ramakanth raised his price target to $105 after reviewing updated survival data from the company’s Phase 3 ROSELLA trial, which is evaluating relacorilant in patients with platinum-resistant ovarian cancer.
The encouraging clinical results prompted analysts to increase their market penetration estimates for the therapy, suggesting that relacorilant could become a significant treatment option in the oncology market. For investors interested in biotech stocks with commercial revenue and late-stage drug pipelines, Corcept Therapeutics offers a unique blend of current income and future clinical catalysts.
Click next to see the following stock...
